Do I really need a knee replacement yet?

Do I really need a replacement yet? In many knees, the answer hinges on whether the problem is a localised patch of cartilage damage (a “pothole”) or widespread wear across most of the joint surface (the “whole road” wearing out), because those two patterns are treated in very different ways.

When cartilage damage is focal, there may be one main defect causing pain, swelling or catching, while the rest of the joint surfaces are relatively preserved. In that situation, joint-preserving strategies are often considered first: symptom management, targeted injection support, and—where appropriate—cartilage restoration procedures aimed at repairing a full‑thickness defect rather than replacing the whole joint. By contrast, with diffuse osteoarthritis and “fully‑blown arthritis” (widespread cartilage loss), cartilage grafting procedures are generally described as not being an alternative to knee replacement, because there is no single repairable patch left to treat. In that setting, the more realistic choices tend to be arthritis management and, when symptoms and disability become significant, arthroplasty.

A knee replacement (knee arthroplasty) is an operation designed to replace the weight‑bearing joint surfaces to relieve pain and disability—most commonly for osteoarthritis—rather than to patch a specific cartilage defect. In other words, it “resurfaces” the joint to deal with advanced, generalised disease affecting large areas of cartilage and bone. This is why knee replacement is usually positioned after non‑operative options have not controlled symptoms sufficiently.

Cartilage repair and restoration procedures (such as ACI/MACI, osteochondral grafting and newer scaffold‑based approaches) aim to restore the damaged cartilage surface in a defined area, with the intent of reducing symptoms and potentially delaying or avoiding knee replacement in appropriately selected people. In a 2024 meta‑analysis of 47 studies (1,993 patients; mean follow‑up ~57 months), several restorative techniques (ACI, MACI, osteochondral autograft and allograft) were associated with significant improvements in common knee outcome measures. Longer follow‑up evidence exists for MACI too: a systematic review of 168 patients reported durable improvements at 10–17 years, with around 7.4% progressing to total knee arthroplasty over that period—supporting its role as a joint‑preserving option for selected defects.

One practical way clinicians describe “where a knee sits” on the spectrum is with simple cartilage grades:

• Early change: softening or fraying (surface wear).
• Deeper injury: a crater-like, full‑thickness defect (a repair “target”).
• End‑stage arthritis: extensive loss across the joint (often described as near “bone‑on‑bone”).

Who actually qualifies for ACI on the NHS?

In England, autologous chondrocyte implantation (ACI) is not positioned as an experimental “add‑on” that only exists in private practice: NICE Technology Appraisal TA477 (last reviewed 4 October 2017) sets out when ACI should be used for symptomatic articular cartilage defects of the knee, and states that NHS commissioners and providers have a responsibility to fund it when a patient and clinician choose it in line with the guidance. That means ACI can be an NHS option for the right type of cartilage problem, even though access is typically through specialist pathways rather than every local hospital offering it.

Although the details vary by centre and by technique, classical ACI is usually described as a two‑stage process. First, a small sample of healthier cartilage is taken (often arthroscopically), the cartilage cells (chondrocytes) are expanded in a laboratory over several weeks, and then a second operation is done to implant the cells back into the defect—historically sealed under a flap of periosteum (shin tissue). Later variants such as MACI use a membrane/scaffold for cell delivery, but the basic point remains: it is more involved than a one‑off arthroscopy, and it depends on being fit for surgery and for a structured rehabilitation programme.

Commissioning is also more centralised than many “day‑to‑day” orthopaedic procedures. An NHS Somerset Integrated Care Board policy (version dated 27 March 2024) states that “autologous chondrocyte implantation as approved by NICE is commissioned by NHS England”, signalling that—when patients meet NICE‑defined indications—ACI is treated as a nationally commissioned specialised service rather than something each local area decides to fund independently. In practice, that tends to mean referral into designated cartilage services, and not every symptomatic cartilage injury will fall within the commissioned criteria.

The people most commonly considered for ACI under NICE‑style criteria are those with a symptomatic, focal full‑thickness cartilage defect (a defined “patch” of loss), in a knee that is otherwise salvageable—meaning alignment and stability are acceptable (or correctable) and there is not widespread cartilage loss across the joint. UK clinical guidance aimed at cartilage repair similarly separates “unstable” focal fraying (sometimes treated with chondroplasty), “small focal patches” (sometimes treated with marrow‑stimulation such as microfracture/nano‑drilling), and larger focal defects where cartilage grafting or cell‑based repair may be considered—while stressing that grafting is not appropriate in “fully‑blown arthritis”.

By contrast, going straight to knee replacement (arthroplasty) on the NHS is more commonly linked to advanced, diffuse osteoarthritis patterns—where pain and disability come from widespread joint-surface wear rather than a single repairable defect. Knee replacement is described as replacing the weight‑bearing joint surfaces to relieve pain and disability, most often for osteoarthritis; this difference in underlying problem is why many patients with established generalised arthritis are channelled towards arthroplasty rather than ACI-type repair.

Private access can look different. One UK cartilage clinic notes that traditional two‑stage ACI/MACI is mostly unavailable privately (and, when offered, tends to be more expensive because of the lab culture phase and second operation), whereas other self‑pay regenerative options are often marketed more prominently. This mismatch between NHS commissioning (tied to TA477 criteria) and private availability is a common reason people hear about “ACI” online but are then offered a different cartilage procedure when exploring self‑pay routes.

When is simple arthroscopic chondroplasty enough?

An arthroscopic “clean‑up” for MRI‑reported “chondral fraying” is usually referring to chondroplasty: a keyhole procedure that trims and smooths frayed or unstable cartilage so it is less likely to catch, flap, or shed further debris. It is best thought of as tidying and stabilising the surface rather than regrowing cartilage.

In NICE’s 2014 briefing on arthroscopic radiofrequency chondroplasty for discrete chondral defects, the stated aim is to debride damaged cartilage and stabilise the defect margins in order to improve mechanical stability and help prevent further cartilage damage. UK private orthopaedic guidance describes a similar stepwise logic: unstable focal areas may be smoothed and stabilised (including radiofrequency techniques), with more “restorative” options reserved for deeper or larger focal loss rather than simple surface fraying.

Where chondroplasty alone may be enough is illustrated by a 2017 case series of isolated mechanical chondroplasty (performed without significant osteoarthritis or meniscal pathology). In that cohort, the average treated lesion size was about 3.3 cm², and most lesions were ICRS grade 2–3 (broadly, partial‑thickness wear rather than a full‑thickness “pothole”). At a mean follow‑up of 31.5 months, patients reported clinically meaningful improvements across multiple outcome scores—supporting the idea that, in carefully selected knees, smoothing an unstable focal area can improve symptoms over roughly 2–3 years.

The main caution is that “fraying” can also sit within a broader degenerative picture. In a large English Hospital Episode Statistics study covering 2007–2017 (157,730 patients), 5.91% went on to knee arthroplasty within 1 year after chondroplasty and 14.22% within 5 years; people aged over 30 with prior chondroplasty were around 17.32 times more likely to have arthroplasty than the general population without chondroplasty. This pattern suggests chondroplasty is often used in knees already on an osteoarthritis pathway, where tidying does not change the underlying biology driving progression.

Practical features that often make chondroplasty alone less likely to be sufficient include:

• Established osteoarthritis changes (rather than one discrete unstable flap).
• Higher‑grade, full‑thickness defects (Outerbridge/ICRS grade 3–4).
• A larger defect area than a simple focal fray.
• Symptoms dominated by constant ache and swelling rather than mainly mechanical catching/locking.

When should you consider regenerative cartilage repair instead?

The shift from “tidying” to regenerative or restorative cartilage repair usually comes when the problem is no longer an unstable surface edge, but a deeper, focal defect where the aim is to fill the missing area with repair tissue, rather than simply smooth it. In this context, restorative techniques include cell‑based repair (ACI/MACI), graft‑based repair (such as osteochondral autograft transfer—OATS/mosaicplasty—or osteochondral allograft), and scaffold‑based approaches designed to support new cartilage formation.

Evidence comparing “tidy‑up” versus augmentation helps explain why surgeons escalate in Outerbridge grade 3–4 lesions. In a 2021 retrospective case series of focal chondral defects, arthroscopic chondroplasty plus bone‑marrow aspirate concentrate (BMAC) and cartilage‑derived matrix (CDM) was associated with better short‑term outcomes than chondroplasty alone: in an age‑matched subanalysis, mean pain scores were lower (VAS 1.7 vs 4.4) and activity/function scores were higher (UCLA 7.1 vs 5.0; KOS‑ADL 87% vs 55%; KOS‑Sports 71% vs 41%). Short‑term rates of injections, further surgery, or conversion to total knee arthroplasty were reported as similar between groups—suggesting the main difference was symptom and function improvement rather than an early divergence in “next surgery” rates.

Across established restorative families (cell and graft procedures), medium‑term outcomes are generally supportive when the knee is appropriately selected. A 2024 systematic review and meta‑analysis (47 studies; 1,993 patients; mean follow‑up 57.2 ± 40.3 months) reported that ACI, MACI, OATS and osteochondral allograft each produced significant improvements in common knee outcome measures (IKDC, Lysholm, Tegner and VAS), often exceeding minimal clinically important and patient‑acceptable thresholds. That pattern supports regenerative repair as a joint‑preservation strategy for tibiofemoral cartilage defects, while still leaving the “best procedure for which defect” question dependent on individual factors.

Patient and joint factors often drive the decision as much as the cartilage itself. UK clinical guidance aimed at focal cartilage problems highlights a stepwise approach—smoothing unstable areas, using marrow stimulation for small focal loss, and moving to grafting or more advanced repair for larger focal defects—while emphasising that cartilage grafting is not appropriate in “fully‑blown arthritis” with widespread loss. In practice, restorative repair is most often considered where there is a symptomatic, focal full‑thickness defect, with a knee that is stable and well aligned (or correctable) and where background osteoarthritis is limited.

Size also matters, but the cut‑offs are not universal. Many specialist pathways use rough bands (described in cm²) to match technique to defect burden—for example, very small defects being treated differently to medium‑sized lesions, and very large or complex defects sometimes pushing towards graft‑based solutions. These figures are best treated as rules of thumb rather than rigid thresholds, because the same “4 cm²” lesion can behave very differently depending on location (e.g. femoral condyle vs trochlea), the state of the underlying bone, and whether mechanics such as alignment are contributing to overload.

For completeness, not all restorative options require an operation in theatre. Some clinics also offer injectable scaffold approaches for suitable focal defects, positioned as an outpatient scaffold treatment sitting alongside surgical restoration options rather than being the same as arthroscopic chondroplasty.

Single‑stage ACI (STACI) versus traditional ACI

For many working‑age patients, the main barrier with an ACI‑type pathway is not the principle of using cartilage cells, but the logistics of two operations—two admissions, two anaesthetics, and two separate recovery windows.

Classic autologous chondrocyte implantation (ACI) is typically described as a two‑stage process: a first procedure to take a cartilage sample, a period of laboratory expansion over several weeks, and then a second operation to implant the cultured cells back into the defect—historically under a periosteal flap (shin tissue). Even where later variants use a membrane/scaffold rather than periosteum, the practical burden remains that it is a staged pathway rather than a one‑off procedure.

A newer “next‑generation” concept is single‑stage delivery of cells on a scaffold. Some clinics describe approaches such as “STACi” as keeping the core idea of using cartilage cells, but changing delivery into a scaffold-based, single-operation format.

The practical appeal of a single‑stage approach is straightforward: one theatre visit and one initial rehabilitation period. In real life, that “one‑go” structure may be particularly valued by people trying to limit time away from work or caring responsibilities, and by those for whom repeated anaesthetics are less attractive.

Evidence and certainty need separating carefully. There are not yet published head‑to‑head trials comparing STACi with MACI/ACI, and most publicly available detail is clinic‑reported rather than drawn from independent long‑term series. To avoid any “behind‑the‑scenes search” language, the limitation is stated plainly here: STACi‑specific outcomes are not well established in the peer‑reviewed literature.

What does exist in the literature is early support for the broader feasibility of single‑stage scaffold‑plus‑cell strategies (not STACi specifically). A phase I human study using allogeneic MSCs mixed with recycled autologous chondrons reported no treatment‑related adverse events up to 12 months, statistically significant clinical improvement, and arthroscopy/MRI descriptions consistent with filled defects and hyaline‑like repair tissue. A separate 19‑patient series using calcified cartilage zone debridement with Hyalofast + BMAC reported significant improvements in multiple KOOS subscales at 18 months. These studies support the general plausibility of single‑stage biological repair, while still leaving STACi’s own durability and comparative performance uncertain.

Access also differs sharply between NHS and self‑pay care in the UK. Some UK clinics publish self‑pay package pricing for single‑stage implantation approaches and note that two‑stage ACI/MACI may be less commonly offered privately; however, published pricing varies by provider and is not the same as clinical effectiveness evidence.

How the MSK Doctors team helps you choose your path

Choosing between cartilage repair, joint-preservation surgery and knee replacement usually comes down to three sets of information gathered in clinic: (1) the pattern of cartilage damage on imaging (focal versus diffuse), (2) the mechanics of how the knee is being loaded (alignment, stability and movement strategy), and (3) the symptom profile (for example, mechanical catching versus constant ache and swelling). This section is intentionally set out as a provider‑neutral decision framework first, with MSK Doctors’ practical set‑up kept to a short, clearly separated note at the end to avoid an advertorial “hard pivot”.

At a consultant-led assessment, the core building blocks are a structured history and examination plus a careful review of any existing MRI and X‑rays. Where the picture is still unclear—particularly when deciding whether damage is genuinely localised or part of broader joint wear—further imaging can be used to clarify the likely cartilage grade and whether there is associated bone change. In MSK Doctors’ pathway, that may include open MRI at Sleaford (NG34), and in selected cases AI-supported MRI reporting (onMRI™) to add consistency when tracking defect features across scans.

Mechanical factors are often treated as decision‑drivers rather than “extras”, because a focal defect that sits in an overloaded compartment can behave very differently once alignment and loading are addressed. Where it adds value, objective movement assessment (MAI Motion® markerless motion capture) can quantify gait features and functional asymmetries, helping to frame whether an offloading strategy (such as an unloader brace) or alignment correction (for example, osteotomy) belongs alongside cartilage restoration rather than after it.

From there, options tend to be discussed as a spectrum rather than a single ‘best’ procedure, with the level matched to the lesion and the whole-knee context:

• Optimised non-operative care and targeted rehabilitation.
• Arthroscopic symptom procedures such as chondroplasty for unstable fraying in selected cases.
• Ultrasound-guided injectable scaffold treatment (ChondroFiller™/Liquid Cartilage™) for suitable focal defects.
• Surgical restoration options such as AMIC, OATS/mosaicplasty, and (in appropriate pathways) ACI/MACI.
• Joint-preservation adjuncts including osteotomy where alignment is a key driver.
• Partial or total knee replacement when the overall joint pattern makes restoration unlikely to meet goals.

Where MSK Doctors fits

MSK Doctors is a CQC-registered group rated “Good” across the five key domains, with main non‑London bases in Sleaford, Lincolnshire (NG34) and Grantham (NG31); appointments are consultant-led and self-referral is accepted without a GP letter and without NHS-style waiting lists. For London-based patients or particularly complex cartilage pathways, the same group also works through its London arm, the London Cartilage Clinic.

Appointments can be booked online via mskdoctors.com for a consultation focused on clarifying whether cartilage repair, joint preservation, or replacement is the most appropriate next step.

1. [1] Allogeneic Mesenchymal Stem Cells Stimulate Cartilage Regeneration and Are Safe for Single‐Stage Cartilage Repair in Humans upon Mixture with Recycled Autologous Chondrons. (2017). https://doi.org/10.1002/stem.2475 https://doi.org/10.1002/stem.2475